regulation
Genentech, Samsung Bioepis, Novartis, Biogen face key antitrust hearing July 28
Novartis, along with Genentech, Samsung Bioepis, and Biogen, faces a key antitrust hearing on July 28.
Markets open original ↗
Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Wed · 15 Jul
regulation
Novartis, along with Genentech, Samsung Bioepis, and Biogen, faces a key antitrust hearing on July 28.
Markets open original ↗
product
Samsung SDI plans to launch an AI-based ESS safety platform by year-end.
Markets open original ↗
partnership
Rocket Lab reportedly made an $8 billion move that could reshape its future, though the headline does not specify the deal's exact nature.
Markets open original ↗
earnings
Kunming Pharmaceutical Group, part of China Resources Pharmaceutical, forecast a first-half net loss of RMB 330-400 million, swinging from a prior-year profit.
Markets open original ↗
partnership
SNT Biotech announced a partnership with Waters Corporation to bring an FDA-cleared at-home HPV cervical cancer screening tool to patients.
Markets open original ↗